Equities researchers at StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a report issued on Saturday. The firm set a “sell” rating on the stock.
Separately, Roth Mkm reiterated a “buy” rating and set a $20.00 price target on shares of Bio-Path in a research report on Monday, July 8th.
Check Out Our Latest Report on Bio-Path
Bio-Path Trading Down 7.3 %
Bio-Path (NASDAQ:BPTH – Get Free Report) last released its quarterly earnings results on Thursday, August 15th. The company reported ($1.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same period in the prior year, the firm posted ($10.60) EPS. As a group, research analysts forecast that Bio-Path will post -6.2 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC bought a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent reporting period. Institutional investors and hedge funds own 5.74% of the company’s stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Further Reading
- Five stocks we like better than Bio-Path
- Comparing and Trading High PE Ratio Stocks
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- 3 Monster Growth Stocks to Buy Now
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- What is a Secondary Public Offering? What Investors Need to Know
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.